Table 1 Plasma miR-92a/miR-638 expression levels in monoclonal gammopathies

From: Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders

 

Number of subjects

Median

Mean

Standard error

Minimum

Maximam

95% CI

Normal

113

1.244

1.388

0.06993

0.2154

3.58

1.249–1.527

Symptomatic MM at diagnosis

62

0.05202

0.1008

0.01899

0.000045

0.8586

0.06285–0.1388

Myeloma subtype

 Ig G

26

0.06107

0.121

0.03378

0.000045

0.8586

0.05146–0.1906

 Ig A

12

0.1508

0.05435

0.1901

0.006992

3.127

0.3020–1.089

 Ig D

3

0.1667

0.2353

0.1423

0.0304

0.5087

−0.3769–0.8475

 Bence–Jones protein

14

0.03866

0.0973

0.04252

0.004289

0.6177

0.005448–0.1892

 Non-secretory myeloma

4

0.06367

0.07089

0.02974

0.01013

0.1461

−0.02376–0.1655

 Plasma cell leukemia

3

0.02628

0.03341

0.01985

0.003151

0.07081

−0.05201–0.1188

Disease status of MM

 Newly diagnosed

62

0.05202

0.1008

0.01899

0.000045

0.8586

0.06285–0.1388

 CR

8

1.494

1.602

0.354

0.2285

3.643

0.7653–2.439

 VGPR

11

0.2176

0.3591

0.09528

0.04138

1.028

0.1468–0.5714

 PR

15

0.8179

0.7967

0.2018

0.1216

1.979

0.5409–1.052

 Stable disease

14

0.3404

0.4251

0.2634

0.003508

0.9965

0.2479–0.6022

 Progressive disease

28

0.06335

0.2018

0.04978

0.003319

0.8586

0.09962–0.3039

SMM

8

0.7943

1.188

0.4791

0.09087

5.242

0.3002–1.348

MGUS

22

0.4055

0.6403

0.1309

0.007652

2.428

0.3681–0.9124

  1. Abbreviations: CI, confidence interval; CR, complete remission; MGUS, monoclonal gammopathy of undermined significance; MM, multiple myeloma; PR, partial response; SMM, smoldering MM; VGPR, very good partial response.
  2. Disease status of multiple myeloma was categorized by International Myeloma Workshop Consensus criteria.20
Back to article page